HBQ Stock Overview
Operates as a consumer and pet health ingredient supplier and incubator in Norway, the United Kingdom, France, Belgium, Europe, Japan, Asia, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Hofseth BioCare ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.11 |
| 52 Week High | NOK 0.25 |
| 52 Week Low | NOK 0.074 |
| Beta | 0.34 |
| 11 Month Change | -10.20% |
| 3 Month Change | -38.72% |
| 1 Year Change | -53.19% |
| 33 Year Change | -82.26% |
| 5 Year Change | -89.37% |
| Change since IPO | -56.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| HBQ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.5% | 0.8% | -1.3% |
| 1Y | -53.2% | -17.5% | 7.4% |
Return vs Industry: HBQ underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: HBQ underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| HBQ volatility | |
|---|---|
| HBQ Average Weekly Movement | 23.5% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HBQ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: HBQ's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 70 | Jon Odegard | www.hofsethbiocare.com |
Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier and incubator in Norway, the United Kingdom, France, Belgium, Europe, Japan, Asia, and the United States. The company’s products include OmeGo, a salmon oil, which offers the full spectrum of fatty acids and omegas found naturally in fresh whole salmon; ProGo, a bioactive peptide for VMS, metabolism, and active nutrition needs; CalGo, an absorbable complex mineral for bone and joint health; CollaGo; and PetGo, a non-soluble protein. The company was incorporated in 2000 and is headquartered in Ålesund, Norway.
Hofseth BioCare ASA Fundamentals Summary
| HBQ fundamental statistics | |
|---|---|
| Market cap | €46.04m |
| Earnings (TTM) | -€11.50m |
| Revenue (TTM) | €21.37m |
2.2x
P/S Ratio-4.0x
P/E RatioIs HBQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HBQ income statement (TTM) | |
|---|---|
| Revenue | NOK 248.08m |
| Cost of Revenue | NOK 187.72m |
| Gross Profit | NOK 60.36m |
| Other Expenses | NOK 193.83m |
| Earnings | -NOK 133.48m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | -0.32 |
| Gross Margin | 24.33% |
| Net Profit Margin | -53.80% |
| Debt/Equity Ratio | 189.8% |
How did HBQ perform over the long term?
See historical performance and comparison